{"cik":1971532,"taxonomy":"us-gaap","tag":"ShareBasedCompensation","label":"Share-based Payment Arrangement, Noncash Expense","description":"Amount of noncash expense for share-based payment arrangement.","entityName":"Telomir Pharmaceuticals, Inc.","units":{"USD":[{"start":"2024-01-01","end":"2024-09-30","val":4805240,"accn":"0001493152-24-044749","fy":2024,"fp":"Q3","form":"10-Q","filed":"2024-11-12"},{"start":"2024-01-01","end":"2024-09-30","val":4805240,"accn":"0001493152-25-021496","fy":2025,"fp":"Q3","form":"10-Q","filed":"2025-11-10"},{"start":"2024-01-01","end":"2024-12-31","val":6867276,"accn":"0001493152-25-004872","fy":2024,"fp":"FY","form":"10-K","filed":"2025-02-04"},{"start":"2024-01-01","end":"2024-12-31","val":6867276,"accn":"0001493152-26-010625","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-17","frame":"CY2024"},{"start":"2025-01-01","end":"2025-03-31","val":1375686,"accn":"0001641172-25-010298","fy":2025,"fp":"Q1","form":"10-Q","filed":"2025-05-14"},{"start":"2025-01-01","end":"2025-03-31","val":1375686,"accn":"0001493152-26-023010","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-14","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":6040136,"accn":"0001641172-25-023970","fy":2025,"fp":"Q2","form":"10-Q","filed":"2025-08-14"},{"start":"2025-01-01","end":"2025-09-30","val":5298278,"accn":"0001493152-25-021496","fy":2025,"fp":"Q3","form":"10-Q","filed":"2025-11-10"},{"start":"2025-01-01","end":"2025-12-31","val":5290329,"accn":"0001493152-26-010625","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-17","frame":"CY2025"},{"start":"2026-01-01","end":"2026-03-31","val":39803,"accn":"0001493152-26-023010","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-14","frame":"CY2026Q1"}]}}